KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Castle Biosciences (CSTL) over the last 3 years, with Q3 2025 value amounting to $54.9 million.

  • Castle Biosciences' Change in Acquisitions & Divestments rose 4918.48% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.8 million, marking a year-over-year increase of 1403.2%. This contributed to the annual value of $183.9 million for FY2024, which is 139.41% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Change in Acquisitions & Divestments is $54.9 million, which was up 4918.48% from $44.0 million recorded in Q2 2025.
  • Castle Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $60.6 million during Q4 2024, with a 5-year trough of $36.2 million in Q2 2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $46.0 million, with a median of $45.0 million in 2023.
  • Data for Castle Biosciences' Change in Acquisitions & Divestments shows a peak YoY increase of 4918.48% (in 2025) and a maximum YoY decrease of 2768.92% (in 2025) over the last 5 years.
  • Castle Biosciences' Change in Acquisitions & Divestments (Quarter) stood at $48.5 million in 2023, then grew by 25.05% to $60.6 million in 2024, then decreased by 9.48% to $54.9 million in 2025.
  • Its last three reported values are $54.9 million in Q3 2025, $44.0 million for Q2 2025, and $36.3 million during Q1 2025.